This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Immunomedics Creates Novel Antibody-Cytokine Conjugates For Cancer Therapy

-- Preclinical Study Presented at 2013 Annual Meeting of the American Association for Cancer Research (AACR) --

-- Study on Mechanism of Cancer Metastasis also Reported --

WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) --  Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the creation of a new class of antibody-cytokine conjugates using the Company's patented DOCK-AND-LOCK™ (DNL™) platform technology. These DNL™ complexes demonstrated potent anti-tumor activity in preclinical studies.

The Company has previously reported the development of antibody-directed interferon-alpha 2b (IFN alpha 2b) complexes. (For more information, please refer to the Company's press release at www.immunomedics.com/pdfs/news/2009/PR04222009A.pdf ). Veltuzumab-IFN alpha 2b is the most advanced product from this group of IFN alpha-based DNL™ complexes, and is currently being developed for improved therapy of B-cell malignancies, partially supported by a grant from the Small Business Innovation Research program of the National Cancer Institute totaling $2.8 million.

While functioning similarly to IFN-alpha in eliciting anti-viral, anti-tumor, and immune-modulating activities, IFN-lambda is being considered as a potential alternative to existing IFN-alpha therapeutic regimens due to its more restricted cellular targets. Antibody-targeted IFN- lambda may further improve its safety, potency and pharmacokinetics.

In the current study, 3 DNL TM complexes of IFN- lambda, designated (E1)- lambda 1, (15)- lambda 1, and (C2)- lambda 1, were generated by site-specifically conjugating IFN- lambda 1 to 3 of the Company's proprietary humanized antibodies, hRS7 (anti-TROP-2), hMN-15 (anti-CEACAM6), and hL243 (anti-HLA-DR), respectively. These antibody-cytokine conjugates were evaluated in human malignant cell lines of cervix, colon, esophagus, lung, liver, and skin.

Targeting of these antibody-cytokine conjugates to antigen-expressing cells markedly increased the amount of IFN- lambda 1 localized at the cell surface. As a result, (E1)- lambda 1 inhibited the in vitro proliferation of the cervical, lung and esophageal cancer cell lines at less than 1 picomolar (pM) concentration, which was 1,000-fold more potent than commercial IFN- lambda 1. Likewise, the anti-proliferation activity of (15)- lambda 1 was enhanced ~100-fold in cervical and esophageal cancer cells, but not in CEACAM6-negative lung cancer cells.

"These promising results, attributable to increased localization and stronger binding to antibody-targeted cells, warrant further exploration as potential cancer therapeutics," remarked Cynthia L. Sullivan, President and Chief Executive Officer.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,912.11 -70.48 -0.42%
S&P 500 1,969.95 -8.96 -0.45%
NASDAQ 4,442.6980 -2.2110 -0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs